CKD-386
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 15
Of
15
Go to page
1
November 01, 2023
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
(clinicaltrials.gov)
- P1 | N=63 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Sep 2023 | Initiation date: Apr 2023 ➔ Jul 2023
Trial completion • Trial completion date • Trial initiation date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
January 26, 2023
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
January 12, 2023
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
September 28, 2022
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
(clinicaltrials.gov)
- P1 | N=64 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
September 23, 2022
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
February 17, 2022
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders
February 03, 2022
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Dyslipidemia • Hypertension • Metabolic Disorders
August 03, 2021
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders
July 28, 2021
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
(clinicaltrials.gov)
- P3; N=100; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Recruiting ➔ Completed
Trial completion • Dyslipidemia • Hypertension • Metabolic Disorders
July 07, 2021
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
(clinicaltrials.gov)
- P1; N=62; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed
Clinical • Trial completion • Dyslipidemia • Hypertension • Metabolic Disorders
July 07, 2021
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386
(clinicaltrials.gov)
- P1; N=66; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed
Clinical • Trial completion • Dyslipidemia • Hypertension • Metabolic Disorders
January 05, 2021
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders
December 17, 2020
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386
(clinicaltrials.gov)
- P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders
March 18, 2020
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
(clinicaltrials.gov)
- P3; N=99; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • Combination therapy • New P3 trial
January 09, 2020
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial
1 to 15
Of
15
Go to page
1